Koroner Kollateral Dolaşım ve Sistemik Hastalıklar
References
Sasayama S, Fujita M, et al. Recent insights into coronary collateral circulation. Circulation. 1992;85:1197-204. doi:10.1161/01.CIR.85.3.1197
Cohen M, Rentrop KP, et al. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation. 1986;74:469-76. doi:10.1161/01.CIR.74.3.469
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation. 2002;106:3143. doi:10.1161/circ.106.25.3143
Rentrop KP, Thornton JC, Feit F, et al. Determinants and protective potential of coronary collaterals in patients with coronary artery disease undergoing angioplasty. Journal of the American College of Cardiology. 1988;12(3):738-748. doi:10.1016/0735-1097(88)90416-2
Van der Hoeven NW, Teunissen PF, Werner GS, et al. Clinical parameters associated with collateral development in patients with chronic total coronary occlusion. Catheterization and Cardiovascular Interventions. 2014;83(1):1-8. doi:10.1002/ccd.25097
Mouquet, F., Cuilleret, F., Susen, S.,et al., 2009. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. European. Heart Journal Apr;30(7):840-9. doi: 10.1093/eurheartj/ehn569
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014 Jan;37(Supplement 1) –S90. DOI:10.2337/dc14-S081.
Waltenberger, J., Lange, J., Kranz, A.,. Vascular endothelial growth factor-A- induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 2000 Jul 11;102(2):185-90. doi: 10.1161/01.cir.102.2.185.
De Vriese, A. S., Verbeuren, T. J., Van de Voorde, J., et.al. . Endothelial dysfunction in diabetes. British journal of pharmacology, 2000 Jul;130(5):963-74. doi: 10.1038/sj.bjp.0703393.
Schaper, W., & Buschmann, I. . Collateral circulation and diabetes. Circulation, 1999 May 4;99(17):2224-6. doi: 10.1161/01.cir.99.17.2224.
Khder, Y., Briançon, S., Petermann, R., et.al. . Shear stress abnormalities contribute to endothelial dysfunction in hypertension but not in type II diabetes. Journal of hypertension, 1998 Nov;16(11):1619-25. doi: 10.1097/00004872-199816110-00008.
Rocic, P. Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome?. Vascular pharmacology, 2012 Nov-Dec;57(5-6):179-86. doi: 10.1016/j.vph.2012.02.001.
Matsunaga, T., Warltier, D.C., Weihrauch, D.W., et.al., Ischemia-induced coronary collateral growth is dependent on vascular en- dothelial growth factor and nitric oxide. Circulation 2000 Dec 19;102(25):3098-103. doi: 10.1161/01.cir.102.25.3098.
Henry, T.D., Annex, B.H., McKendall, G.R.,et al., . The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003 Mar 18;107(10):1359-65. doi: 10.1161/01.cir.0000061911.47710.8a
Waltenberger, J., Lange, J., Kranz, A.,. Vascular endothelial growth factor-A- induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 2000 Jul 11;102(2):185-90. doi: 10.1161/01.cir.102.2.185.
Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, and the future. Circulation. 2000;102(1):73-86. DOI:10.1161/01.CIR.102.1.73.
Silvestre JS, Lévy BI. Molecular basis of therapeutic angiogenesis: insights from experimental and clinical studies. Physiological Reviews. 2008;88(4):1181-1220. DOI:10.1152/physrev.00041.2007.
Hattan N, Chilian WM, Park F, et.al. Restoration of coronary collateral growth in the Zucker obese rat: impact of VEGF and ecSOD. Basic research in cardiology 2007 May;102(3):217-23. doi: 10.1007/s00395-007-0646-3
Guerci, B., Böhme, P., Kearney-Schwartz, A., et.al., 2001. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metabolism Journal 27, 436–447.
Reed, R., Kolz, C., Potter, B., et.al. The mechanistic basis for the disparate ef- fects of angiotensin II on coronary collateral growth. Arteriosclerosis, thrombosis, and vascular biology vol. 28,1 (2008): 61-7. doi:10.1161/ATVBAHA.107.154294
Meisner, J.K., Price, R.J., Spatial and temporal coordination of bone marrow- derived cell activity during arteriogenesis: regulation of the endogenous response and therapeutic implications. Microcirculation (New York, N.Y. : 1994) vol. 17,8 (2010): 583-99. doi:10.1111/j.1549-8719.2010.00051.x
Kocaman, S.A., Sahinarslan, A., Akyel, A., et.al. The association of circulating monocyte count with coronary collateral growth in patients with diabetes mellitus. Acta diabetologica vol. 47,1 (2010): 49-54. doi:10.1007/s00592-009-0097-4
Njolstad I, Arnesen E. Preinfarction blood pressure and smoking are determinants for a fatal outcome of myocardial infarction: a prospective analysis from the Finnmark Study. Archives of internal medicine vol. 158,12 (1998): 1326-32. doi:10.1001/archinte.158.12.1326
Schmieder RE. End organ damage in hypertension. Deutsches Arzteblatt international vol. 107,49 (2010): 866-73. doi:10.3238/arztebl.2010.0866
Seiler C, Stoller M, Pitt B, et.al. The human coronary collateral circulation: development and clinical importance. European heart journal vol. 34,34 (2013): 2674-82. doi:10.1093/eurheartj/eht195
Is there an association between hypertension and the development of coronary collateral flow? Journal of Human Hypertension (2005) 19, 757–759. doi:10.1038/sj.jhh.1001906; published online 23 June 2005
Koerselman, J et al. “High blood pressure is inversely related with the presence and extent of coronary collaterals.” Journal of human hypertension vol. 19,10 (2005): 809-17. doi:10.1038/sj.jhh.1001917
Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122):524-526. DOI:10.1038/327524a0.
Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension? Current opinion in nephrology and hypertension vol. 12,2 (2003): 181-7. doi:10.1097/00041552-200303000-00009
Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003;107(22):2864-2869. DOI:10.1161/01.CIR.0000069825.36125.B4.
Koerselman J, van der Graaf Y, de Jaegere PP, et al. Coronary collaterals: an important and underexposed aspect of coronary artery disease. Circulation. 2003;107(19):2507-2511. DOI:10.1161/01.CIR.0000068315.18468.D5.
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Journal of the American College of Cardiology vol. 35,3 (2000): 569-82. doi:10.1016/s0735-1097(99)00630-0
Rye, Kerry-Anne, and Philip J Barter. “Cardioprotective functions of HDLs.” Journal of lipid research vol. 55,2 (2014): 168-79. doi:10.1194/jlr.R039297
Tan, Joanne T M et al. “The role of high-density lipoproteins in the regulation of angiogenesis.” Cardiovascular research vol. 106,2 (2015): 184-93. doi:10.1093/cvr/cvv104
Fang L, Choi SH, Baek JS, et al. Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature. 2013;498:118–122.DOI: 10.1038/natur e12166.
Lee, Seonhwa et al. “Cholesterol Efflux and Collateral Circulation in Chronic Total Coronary Occlusion: Effect-Circ Study.” Journal of the American Heart Association vol. 10,5 (2021): e019060. doi:10.1161/JAHA.120.019060
Libby, Peter et al. “Inflammation in atherosclerosis: from pathophysiology to practice.” Journal of the American College of Cardiology vol. 54,23 (2009): 2129-38. doi:10.1016/j.jacc.2009.09.009
Liao, James K, and Ulrich Laufs. “Pleiotropic effects of statins.” Annual review of pharmacology and toxicology vol. 45 (2005): 89-118. doi:10.1146/annurev.pharmtox.45.120403.095748
Klein, I, and K Ojamaa. “Thyroid hormone and the cardiovascular system.” The New England journal of medicine vol. 344,7 (2001): 501-9. doi:10.1056/NEJM200102153440707
Ojamaa, K et al. “Acute effects of thyroid hormone on vascular smooth muscle.” Thyroid : official journal of the American Thyroid Association vol. 6,5 (1996): 505-12. doi:10.1089/thy.1996.6.505
Hak, A E et al. “Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.” Annals of internal medicine vol. 132,4 (2000): 270-8. doi:10.7326/0003-4819-132-4-200002150-00004
Ballı, Mehmet et al. “The relationship between serum thyroid hormone levels, subclinical hypothyroidism, and coronary collateral circulation in patients with stable coronary artery disease.” Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir vol. 44,2 (2016): 130-6. doi:10.5543/tkda.2015.00905
Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008;29(1):76-131. DOI:10.1210/er.2006-0043.
Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725-1735. DOI:10.1161/CIRCULATIONAHA.106.678326.
Boushey CJ, Beresford SA, Omenn GS, et.al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA vol. 274,13 (1995): 1049-57. doi:10.1001/jama.1995.03530130055028
Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as risk factor for occlusive vascular diease. Annual review of nutrition vol. 12 (1992): 279-98. doi:10.1146/annurev.nu.12.070192.001431
McCully, K S. “Homocysteine and vascular disease.” Nature medicine vol. 2,4 (1996): 386-9. doi:10.1038/nm0496-386
Nagai Y, Tasaki H, Miyamoto M, et al. Plasma level of homocysteine is inversely-associated with the development of collateral circulation in patients with single-vessel coronary artery disease. Circulation journal : official journal of the Japanese Circulation Society vol. 66,2 (2002): 158-62. doi:10.1253/circj.66.158
Keçebaş M, Beşli F, Alişir MF, et.al. Koroner Arter Hastalarında Koroner Kollateral Gelişiminin Risk Faktörleri İle Arasındaki İlişki. Uludağ Tıp Derg. 2012;38(3):173-7.
Sayar N, Terzi S, Bilsel T, et al. Plasma homocysteine concentration in patients with poor or good coronary collaterals. Circulation journal : official journal of the Japanese Circulation Society vol. 71,2 (2007): 266-70. doi:10.1253/circj.71.266
Cohen M, Rentrop KP, et al. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation. 1986;74:469-76. doi:10.1161/01.CIR.74.3.469
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation. 2002;106:3143. doi:10.1161/circ.106.25.3143
Rentrop KP, Thornton JC, Feit F, et al. Determinants and protective potential of coronary collaterals in patients with coronary artery disease undergoing angioplasty. Journal of the American College of Cardiology. 1988;12(3):738-748. doi:10.1016/0735-1097(88)90416-2
Van der Hoeven NW, Teunissen PF, Werner GS, et al. Clinical parameters associated with collateral development in patients with chronic total coronary occlusion. Catheterization and Cardiovascular Interventions. 2014;83(1):1-8. doi:10.1002/ccd.25097
Mouquet, F., Cuilleret, F., Susen, S.,et al., 2009. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. European. Heart Journal Apr;30(7):840-9. doi: 10.1093/eurheartj/ehn569
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014 Jan;37(Supplement 1) –S90. DOI:10.2337/dc14-S081.
Waltenberger, J., Lange, J., Kranz, A.,. Vascular endothelial growth factor-A- induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 2000 Jul 11;102(2):185-90. doi: 10.1161/01.cir.102.2.185.
De Vriese, A. S., Verbeuren, T. J., Van de Voorde, J., et.al. . Endothelial dysfunction in diabetes. British journal of pharmacology, 2000 Jul;130(5):963-74. doi: 10.1038/sj.bjp.0703393.
Schaper, W., & Buschmann, I. . Collateral circulation and diabetes. Circulation, 1999 May 4;99(17):2224-6. doi: 10.1161/01.cir.99.17.2224.
Khder, Y., Briançon, S., Petermann, R., et.al. . Shear stress abnormalities contribute to endothelial dysfunction in hypertension but not in type II diabetes. Journal of hypertension, 1998 Nov;16(11):1619-25. doi: 10.1097/00004872-199816110-00008.
Rocic, P. Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome?. Vascular pharmacology, 2012 Nov-Dec;57(5-6):179-86. doi: 10.1016/j.vph.2012.02.001.
Matsunaga, T., Warltier, D.C., Weihrauch, D.W., et.al., Ischemia-induced coronary collateral growth is dependent on vascular en- dothelial growth factor and nitric oxide. Circulation 2000 Dec 19;102(25):3098-103. doi: 10.1161/01.cir.102.25.3098.
Henry, T.D., Annex, B.H., McKendall, G.R.,et al., . The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003 Mar 18;107(10):1359-65. doi: 10.1161/01.cir.0000061911.47710.8a
Waltenberger, J., Lange, J., Kranz, A.,. Vascular endothelial growth factor-A- induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 2000 Jul 11;102(2):185-90. doi: 10.1161/01.cir.102.2.185.
Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, and the future. Circulation. 2000;102(1):73-86. DOI:10.1161/01.CIR.102.1.73.
Silvestre JS, Lévy BI. Molecular basis of therapeutic angiogenesis: insights from experimental and clinical studies. Physiological Reviews. 2008;88(4):1181-1220. DOI:10.1152/physrev.00041.2007.
Hattan N, Chilian WM, Park F, et.al. Restoration of coronary collateral growth in the Zucker obese rat: impact of VEGF and ecSOD. Basic research in cardiology 2007 May;102(3):217-23. doi: 10.1007/s00395-007-0646-3
Guerci, B., Böhme, P., Kearney-Schwartz, A., et.al., 2001. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metabolism Journal 27, 436–447.
Reed, R., Kolz, C., Potter, B., et.al. The mechanistic basis for the disparate ef- fects of angiotensin II on coronary collateral growth. Arteriosclerosis, thrombosis, and vascular biology vol. 28,1 (2008): 61-7. doi:10.1161/ATVBAHA.107.154294
Meisner, J.K., Price, R.J., Spatial and temporal coordination of bone marrow- derived cell activity during arteriogenesis: regulation of the endogenous response and therapeutic implications. Microcirculation (New York, N.Y. : 1994) vol. 17,8 (2010): 583-99. doi:10.1111/j.1549-8719.2010.00051.x
Kocaman, S.A., Sahinarslan, A., Akyel, A., et.al. The association of circulating monocyte count with coronary collateral growth in patients with diabetes mellitus. Acta diabetologica vol. 47,1 (2010): 49-54. doi:10.1007/s00592-009-0097-4
Njolstad I, Arnesen E. Preinfarction blood pressure and smoking are determinants for a fatal outcome of myocardial infarction: a prospective analysis from the Finnmark Study. Archives of internal medicine vol. 158,12 (1998): 1326-32. doi:10.1001/archinte.158.12.1326
Schmieder RE. End organ damage in hypertension. Deutsches Arzteblatt international vol. 107,49 (2010): 866-73. doi:10.3238/arztebl.2010.0866
Seiler C, Stoller M, Pitt B, et.al. The human coronary collateral circulation: development and clinical importance. European heart journal vol. 34,34 (2013): 2674-82. doi:10.1093/eurheartj/eht195
Is there an association between hypertension and the development of coronary collateral flow? Journal of Human Hypertension (2005) 19, 757–759. doi:10.1038/sj.jhh.1001906; published online 23 June 2005
Koerselman, J et al. “High blood pressure is inversely related with the presence and extent of coronary collaterals.” Journal of human hypertension vol. 19,10 (2005): 809-17. doi:10.1038/sj.jhh.1001917
Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122):524-526. DOI:10.1038/327524a0.
Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension? Current opinion in nephrology and hypertension vol. 12,2 (2003): 181-7. doi:10.1097/00041552-200303000-00009
Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation. 2003;107(22):2864-2869. DOI:10.1161/01.CIR.0000069825.36125.B4.
Koerselman J, van der Graaf Y, de Jaegere PP, et al. Coronary collaterals: an important and underexposed aspect of coronary artery disease. Circulation. 2003;107(19):2507-2511. DOI:10.1161/01.CIR.0000068315.18468.D5.
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Journal of the American College of Cardiology vol. 35,3 (2000): 569-82. doi:10.1016/s0735-1097(99)00630-0
Rye, Kerry-Anne, and Philip J Barter. “Cardioprotective functions of HDLs.” Journal of lipid research vol. 55,2 (2014): 168-79. doi:10.1194/jlr.R039297
Tan, Joanne T M et al. “The role of high-density lipoproteins in the regulation of angiogenesis.” Cardiovascular research vol. 106,2 (2015): 184-93. doi:10.1093/cvr/cvv104
Fang L, Choi SH, Baek JS, et al. Control of angiogenesis by AIBP-mediated cholesterol efflux. Nature. 2013;498:118–122.DOI: 10.1038/natur e12166.
Lee, Seonhwa et al. “Cholesterol Efflux and Collateral Circulation in Chronic Total Coronary Occlusion: Effect-Circ Study.” Journal of the American Heart Association vol. 10,5 (2021): e019060. doi:10.1161/JAHA.120.019060
Libby, Peter et al. “Inflammation in atherosclerosis: from pathophysiology to practice.” Journal of the American College of Cardiology vol. 54,23 (2009): 2129-38. doi:10.1016/j.jacc.2009.09.009
Liao, James K, and Ulrich Laufs. “Pleiotropic effects of statins.” Annual review of pharmacology and toxicology vol. 45 (2005): 89-118. doi:10.1146/annurev.pharmtox.45.120403.095748
Klein, I, and K Ojamaa. “Thyroid hormone and the cardiovascular system.” The New England journal of medicine vol. 344,7 (2001): 501-9. doi:10.1056/NEJM200102153440707
Ojamaa, K et al. “Acute effects of thyroid hormone on vascular smooth muscle.” Thyroid : official journal of the American Thyroid Association vol. 6,5 (1996): 505-12. doi:10.1089/thy.1996.6.505
Hak, A E et al. “Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study.” Annals of internal medicine vol. 132,4 (2000): 270-8. doi:10.7326/0003-4819-132-4-200002150-00004
Ballı, Mehmet et al. “The relationship between serum thyroid hormone levels, subclinical hypothyroidism, and coronary collateral circulation in patients with stable coronary artery disease.” Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir vol. 44,2 (2016): 130-6. doi:10.5543/tkda.2015.00905
Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008;29(1):76-131. DOI:10.1210/er.2006-0043.
Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725-1735. DOI:10.1161/CIRCULATIONAHA.106.678326.
Boushey CJ, Beresford SA, Omenn GS, et.al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA vol. 274,13 (1995): 1049-57. doi:10.1001/jama.1995.03530130055028
Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as risk factor for occlusive vascular diease. Annual review of nutrition vol. 12 (1992): 279-98. doi:10.1146/annurev.nu.12.070192.001431
McCully, K S. “Homocysteine and vascular disease.” Nature medicine vol. 2,4 (1996): 386-9. doi:10.1038/nm0496-386
Nagai Y, Tasaki H, Miyamoto M, et al. Plasma level of homocysteine is inversely-associated with the development of collateral circulation in patients with single-vessel coronary artery disease. Circulation journal : official journal of the Japanese Circulation Society vol. 66,2 (2002): 158-62. doi:10.1253/circj.66.158
Keçebaş M, Beşli F, Alişir MF, et.al. Koroner Arter Hastalarında Koroner Kollateral Gelişiminin Risk Faktörleri İle Arasındaki İlişki. Uludağ Tıp Derg. 2012;38(3):173-7.
Sayar N, Terzi S, Bilsel T, et al. Plasma homocysteine concentration in patients with poor or good coronary collaterals. Circulation journal : official journal of the Japanese Circulation Society vol. 71,2 (2007): 266-70. doi:10.1253/circj.71.266
Pages
89-102
Published
October 8, 2024
Copyright (c) 2024 Academician Publishing Book Portal
